BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer-Reference-Cited by-同舟云学术

BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer

Published:2024-10 Issue: Volume:210 Page:114290
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ambrosini Margherita,Tougeron David,Modest Dominik,Guimbaud Rosine,Kopetz Scott,Decraecker Marie,Kim Stefano,Coutzac Clelia,Perkins Geraldine,Alouani Emily,Marmorino Federica,Pernot Simon,Sinicrope Frank A,Elez Elena,Parent Pauline,Cremolini Chiara,Pietrantonio Filippo,Lonardi Sara,Gallois Claire,Taieb Julien

Funder

Les Laboratories Pierre Fabre

Universite Paris Cite

Publisher

Elsevier BV

Reference39 articles.

1. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Cervantes;Ann Oncol,2023

2. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer;Sargent;J Clin Oncol,2010

3. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies;Taieb;Ann Oncol,2019

4. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials;Taieb;Ann Oncol,2023

5. Investigating the poor outcomes ofBRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials;Seligmann;Ann Oncol,2017